| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
C6 neuroastrocytoma cell numbers are quantitatively decreased by aminoacetic acid (AOAA). The G0/G1 phase cell count was greatly raised by aminoacetic acid treatment, and the G2/M phase and one S phase cell purification greatly boosted the cell count as well. The number of cells in the cell division phase significantly decreased after being treated with aminoacetic acid. Aminoacetic acid dramatically raises the proportion of mitochondria and early cells. Cell aging can be inhibited by treating cells with 1 mM or 5 mM aminooxyacetic acid [1]. Compared to cells cultivated with glutamine-supported cells, AOA has a stronger inhibitory effect on the proliferation of glutamine-supported cells [3].
|
|---|---|
| ln Vivo |
Five minutes after the injection of aminooxyacetic acid (AOAA), the amount of GABA in the cerebellum and throughout the brain increases dramatically. This accumulation of GABA occurs initially quite quickly. Two to six hours after the administration of aminooxyacetic acid, the final buildup of GABA slowed down and achieved a maximal level (GABA levels increased by roughly 250% 24 hours after aminooxyacetic acid therapy). Two to six hours after the administration of aminooxyacetic acid, convulsions started. full extension. Convulsions are nearly identical to sleep 24 hours following therapy with aminooxyacetic acid [2].
|
| References |
[1]. Wang C, et al. Malate-aspartate shuttle inhibitor aminooxyacetic acid leads to decreased intracellular ATP levels and altered cell cycle of C6 glioma cells by inhibiting glycolysis. Cancer Lett. 2016 Aug 1;378(1):1-7.
[2]. Pagliusi SR, et al. Aminooxyacetic acid induced accumulation of GABA in the rat brain. Interaction with GABA receptors and distribution in compartments. Naunyn Schmiedebergs Arch Pharmacol. 1983 Apr;322(3):210-5. [3]. Korangath P, et al. Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate. Clin Cancer Res. 2015 Jul 15;21(14):3263-73. |
| Additional Infomation |
(aminooxy)acetic acid is a member of the class of hydroxylamines that is acetic acid substituted at postion 2 by an aminooxy group. It is a compound which inhibits aminobutyrate aminotransferase activity in vivo, resulting in increased levels of gamma-aminobutyric acid in tissues. It has a role as a nootropic agent, an EC 4.2.1.22 (cystathionine beta-synthase) inhibitor, an EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor and an anticonvulsant. It is an amino acid, a member of hydroxylamines and a monocarboxylic acid. It is a conjugate acid of an (aminooxy)acetate.
Aminooxyacetic acid has been reported in Arabidopsis thaliana with data available. A compound that inhibits aminobutyrate aminotransferase activity in vivo, thereby raising the level of gamma-aminobutyric acid in tissues. |
| Molecular Formula |
C2H5NO3
|
|---|---|
| Molecular Weight |
91.066
|
| Exact Mass |
90.019
|
| CAS # |
645-88-5
|
| Related CAS # |
Aminooxyacetic acid hemihydrochloride;2921-14-4
|
| PubChem CID |
286
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.375g/ml
|
| Boiling Point |
327℃
|
| Melting Point |
138℃
|
| Flash Point |
151℃
|
| LogP |
-3.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
6
|
| Complexity |
52.8
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NOCC(O)=O
|
| InChi Key |
NQRKYASMKDDGHT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C2H5NO3/c3-6-1-2(4)5/h1,3H2,(H,4,5)
|
| Chemical Name |
2-aminooxyacetic acid
|
| Synonyms |
U-7524; AOAA, Aminooxyacetic acid, 2-Aminooxyacetic acid, U 7524, U7524
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 10.9806 mL | 54.9028 mL | 109.8056 mL | |
| 5 mM | 2.1961 mL | 10.9806 mL | 21.9611 mL | |
| 10 mM | 1.0981 mL | 5.4903 mL | 10.9806 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
